Skip to Main Content
Services Talent Knowledge
Site Search
Menu

PressRelease

November 30, 2022

Meghan Tuma Joins Barclay Damon

November 30, 2022—Barclay Damon announces Meghan Tuma, associate, has joined Barclay Damon’s Torts & Products Liability Defense, Professional Liability, Insurance Coverage & Regulation, and Commercial Litigation Practice Areas. Her primary office location is New York City.

Tuma has experience representing health care providers, hospital representatives, and insurance carriers in medical malpractice matters. She also has experience representing school districts and municipalities in commercial litigation matters, including business-related disputes, in state and federal court. During law school, Tuma interned as risk management general counsel and in a regulatory health law department, where she focused on the transactional side of health law. Additionally, she participated in Albany Law School’s health law clinic.

Barclay Damon attorneys team across offices and practices to provide customized, targeted solutions grounded in industry knowledge and a deep understanding of our clients’ businesses. With nearly 300 attorneys, Barclay Damon is a leading law firm that operates from a strategic platform of offices located in the Northeastern United States and Toronto. For more information, visit our award-winning website at barclaydamon.com.
 

Subscribe

Click here to sign up for alerts, blog posts, and firm news.

Featured Media

Alerts

Massachusetts Federal Court Permits Sharing Clause in Protective Order in Products Liability Case

Alerts

NYS Court of Appeals Holds That Parent May Not Recover for Emotional Injuries in Prenatal-Injury Case

Alerts

Smarter Inventory Management for Pharmacies: Navigating Online Marketplace Compliance

Alerts

Emergency Wine Run, Now Legal: New York State Opens Retail-to-Retail Sales

Alerts

California's Updated Privacy Regulations: Automated Decisionmaking Technology, Cybersecurity Audits, and Risk Assessments, Part 1

Alerts

Pharmacies on High Alert: Optum Rx's 25-Percent Therapeutic-Class Cap Creates Major Legal, Operational, and Competitive Risks